Hikma Pharmaceuticals PLC (HKMPF) Comparison with companies in other sectors?

Hikma Pharmaceuticals PLC has a share price of 220.43M. You can analyze Hikma Pharmaceuticals PLC (HKMPF) competitors across different market sectors through stock heatmaps.

What are HKMPF's NET and operating margins?

Hikma Pharmaceuticals PLC (HKMPF) operating margin is around 0.20, and net profit margin is approximately 0.11 as of the latest reports.

In what way does HKMPF's earnings per share (EPS) trend reflect its financial momentum?

Hikma Pharmaceuticals PLC (HKMPF) EPS is 1.61 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Hikma Pharmaceuticals PLC is 17.37, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Hikma Pharmaceuticals PLC?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Hikma Pharmaceuticals PLC like P/E which is 17.28, P/B which is 2.69, and PEG which is 0.65. Compare them with sector averages to evaluate if the stock is priced fairly.

Hikma Pharmaceuticals PLC

HKMPF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$27.96

$1.16(4.33%)

Fundamental Analysis of Hikma Pharmaceuticals PLC (HKMPF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$1.61

P/E Ratio

17.37

ROE

0.16%

Net Margin

0.11%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$6.16B

Shares OutstandingTotal number of shares issued

$220.43M

Book Value/ShareNet worth per share

$10.46

Revenue/ShareAnnual revenue per share

$14.10

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.61

Net MarginNet income as percentage of revenue

11.48%

Operating MarginOperating income as percentage of revenue

19.57%

ROEReturn on shareholders' equity

15.62%

ROAReturn on total assets

6.99%

ROCEReturn on capital employed

19.40%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$1.80

Cash/ShareCash and equivalents per share

$0.96

FCF YieldFree cash flow as percentage of market cap

6.47%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.80

Dividend YieldAnnual dividend as percentage of stock price

2.86%

Financial Ratios Analysis data is not available for HKMPFFinancial Ratios Analysis details for HKMPF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for HKMPFSector Benchmarking details for HKMPF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Hikma Pharmaceuticals PLC Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Hikma Pharmaceuticals PLC. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Hikma Pharmaceuticals PLC's unique business strengths and challenges.

Key Financial Metrics for Hikma Pharmaceuticals PLC

For Hikma Pharmaceuticals PLC, essential financial indicators include EPS 1.61, PE 17.37, and ROE 0.16. These key ratios reveal insights into Hikma Pharmaceuticals PLC's profitability, valuation, and operational health. Understanding these metrics enables you to compare Hikma Pharmaceuticals PLC with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Hikma Pharmaceuticals PLC

Metrics like Net Margin 11.48% and ROA 6.99% shed light on how well Hikma Pharmaceuticals PLC is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Hikma Pharmaceuticals PLC can sustain its operations and continue growing in the future.

Valuation and Market Position of Hikma Pharmaceuticals PLC

Using ratios such as P/B Ratio 2.69 and PEG Ratio 0.65, investors can assess whether Hikma Pharmaceuticals PLC is appropriately valued based on its financials and growth potential. These figures, combined with Hikma Pharmaceuticals PLC's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Hikma Pharmaceuticals PLC

Financial health indicators, such as Debt/Equity Ratio 0.57 and Cash Flow $1.80, provide a snapshot of Hikma Pharmaceuticals PLC's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Hikma Pharmaceuticals PLC, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Hikma Pharmaceuticals PLC

Investing in Hikma Pharmaceuticals PLC based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Hikma Pharmaceuticals PLC focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;